Literature DB >> 31577543

Atypical, milder presentation in a child with CC2D2A and KIDINS220 variants.

Zena Lam1, Shadi Albaba2, Ddd Study3, Meena Balasubramanian4,5.   

Abstract

With the increasing availability and clinical use of exome and whole-genome sequencing, reverse phenotyping is now becoming common practice in clinical genetics. Here, we report a patient identified through the Wellcome Trust Deciphering Developmental Disorders study who has homozygous pathogenic variants in CC2D2A and a de-novo heterozygous pathogenic variant in KIDINS220. He presents with developmental delay, intellectual disability, and oculomotor apraxia. Reverse phenotyping has demonstrated that he likely has a composite phenotype with contributions from both variants. The patient is much more mildly affected than those with Joubert Syndrome or Spastic paraplegia, intellectual disability, nystagmus, and obesity, the conditions associated with CC2D2A and KIDINS220 respectively, and therefore, contributes to the phenotypic variability associated with the two conditions.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 31577543     DOI: 10.1097/MCD.0000000000000298

Source DB:  PubMed          Journal:  Clin Dysmorphol        ISSN: 0962-8827            Impact factor:   0.816


  2 in total

1.  Update of genetic variants in CEP120 and CC2D2A-With an emphasis on genotype-phenotype correlations, tissue specific transcripts and exploring mutation specific exon skipping therapies.

Authors:  Miguel Barroso-Gil; Eric Olinger; Simon A Ramsbottom; Elisa Molinari; Colin G Miles; John A Sayer
Journal:  Mol Genet Genomic Med       Date:  2021-01-24       Impact factor: 2.473

2.  Kidins220/ARMS modulates brain morphology and anxiety-like traits in adult mice.

Authors:  Amanda Almacellas-Barbanoj; Martina Albini; Annyesha Satapathy; Fanny Jaudon; Caterina Michetti; Alicja Krawczun-Rygmaczewska; Huiping Huang; Francesca Manago; Francesco Papaleo; Fabio Benfenati; Fabrizia Cesca
Journal:  Cell Death Discov       Date:  2022-02-09
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.